Report #2830934

Received Mar 12, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 53 yrs
State: NV
Recovered: Unknown
Vaccinated: Feb 6, 2025
Onset: Feb 6, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	93kk4	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Shingrix early second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 53-year-old male patient who received Herpes zoster (Shingrix) (batch number 93kk4, expiry date 31-JAN-2027) for prophylaxis. Concomitant products included Varicella zoster vaccine rgE (CHO) (Shingrix). On 06-FEB-2025, the patient received the 2nd dose of Shingrix. On 06-FEB-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: Shingrix early second dose). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 05-MAR-2025 The pharmacist reported a patient received the first dose of Shingrix on 13th January 2025. The patient was not immunocompromised. The reporter consented to follow up. The patient received 2nd dose of Shingrix, earlier than the recommended interval, which led to shortening of vaccination schedule.